The 2mg dose is a receptor adaptation phase, not a results phase
These findings led to Phase I and II clinical trials of T4 eyedrops (RGN-259) for dry eye and neurotrophic keratopathy, making the ocular surface one of the most clinically advanced use areas for the broader T4/TB-500 compound class
These peptides work through distinct yet complementary mechanisms to optimize the body's natural repair processes, making this blend particularly effective for complex injuries requiring comprehensive healing support
Your body begins making new red blood cells within 48 to 72 hours after your injection, at which time you can start to feel the positive effects
Olympias compounded NAD+ may be administered via IV, IM, or SubQ routes, depending on your care plan
The published research literature has investigated: Angiogenic effects (formation of new blood vessels in damaged tissue) VEGFR2 receptor activity modulation Growth factor expression Tissue protection in gastrointestinal, vascular, and musculoskeletal contexts Wound healing in multiple tissue models GHK-Cu mechanisms